Scottish Medicines Consortium recommends elmiron® for the treatment of bladder pain syndrome

Click here for downloadable file for journalists.

Consilient Health welcomes the decision by the Scottish Medicines Consortium (SMC) to recommend elmiron® (pentosan polysulfate sodium) for bladder pain syndrome (BPS) within its marketing authorisation1. elmiron® is indicated for the treatment of bladder pain syndrome characterised by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of mictuition. elmiron® is the only licensed oral medication for BPS with glomerulations or Hunner’s lesions (referred to as interstitial cystitis/BPS)2,3.

SMC is the national source of advice on the clinical and cost-effectiveness of all new medicines for NHSScotland. Its recommendation came after Consilient Health agreed a Patient Access Scheme with the SMC which will make elmiron® available to NHSScotland.

Mr Thomas Lam, Consultant Urological Surgeon and Honorary Senior Clinical Lecturer, Aberdeen Royal Infirmary and Academic Urology Unit, University of Aberdeen said: “I’m pleased that the SMC has approved the use of elmiron®. BPS is challenging to manage and difficult to treat; there is no standard treatment and a range of treatment options is crucial. elmiron® is an effective and well-tolerated medicine in BPS, and its approval will benefit patients by increasing the available treatment options.”

Susannah Fraser, Communication and Media Manager, Bladder Health UK said: “BPS is a debilitating condition and has a considerable detrimental impact on the individual’s lifestyle, ability to work, emotional health and relationships. Their quality of life is hugely compromised. For individuals in Scotland to be able to access elmiron® on the NHS is really good news.”

Amanda Paxon, Consilient Health UK Country Manager Pharmaceuticals said: “This is a condition with a significant unmet clinical need and the company is delighted that elmiron® has been recommended for the treatment of IC/BPS”.

 

References

1. Scottish Medicines Consortium November 2019. https://www.scottishmedicines.org.uk/about-us/latest-updates/ (accessed November 2019).
2. bene-Arzneimittel GmbH. elmiron® (pentosan polysulfate sodium) 100 mg hard capsules Summary of Product Characteristics. July 2019.
3. Committee for Medicinal Products for Human Use (CHMP) Assessment report elmiron® EMA/287422/2017 23 March 2016. elmiron® is indicated for the treatment of bladder pain syndrome characterised by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Public_assessment_report/human/004246/WC500229392.pdf

 

 

View more news and events